Fig. 4

MiR-589-5p directly targets TRAF6 in laryngocarcinoma cells. a RIP experiments demonstrated the obvious enrichment of TRAF6 but not SORT1, ABL2 or NPTN in Bio-miR-589-5p groups. b Ago2-RIP assays examined that the apparent enrichment of LOXL1-AS1, miR-589-5p and TRAF6 in anti-Ago2 groups. c RNA pull down assay disclosed the high enrichment of LOXL1-AS1 and TRAF6 in Bio-miR-589-5p-WT groups. d Luciferase reporter assays detected the luciferase activity of pmirGLO/3′UTR-WT/Mut in Tu-177 and M4E cells co-transfected with miR-NC, miR-589-5p mimics, or miR-589-5p mimics + LOXL1-AS1. **p < 0.01